Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Lilexin** is the Chinese prescription brand of omega-3 fatty acid ethyl esters 90 soft capsules developed by Gowell for treatment of hypertriglyceridemia. It is an oral, highly concentrated mixture of omega-3 fatty-acid ethyl esters, principally eicosapentaenoic acid and docosahexaenoic acid ethyl esters. The product lowers triglycerides primarily by reducing hepatic very-low-density-lipoprotein synthesis and secretion while promoting triglyceride breakdown in very-low-density lipoproteins and chylomicrons. Gowell states that Lilexin was approved in China for lowering triglycerides in adults with severe hypertriglyceridemia. ([cdgowell.com](https://www.cdgowell.com/newsinfo.aspx?ContentID=1287&Type=12))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omega-3 fatty acid ethyl esters.